{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:03:08Z","timestamp":1761519788913,"version":"build-2065373602"},"reference-count":15,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2007,9,1]],"date-time":"2007-09-01T00:00:00Z","timestamp":1188604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,9,1]],"date-time":"2007-09-01T00:00:00Z","timestamp":1188604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2007,9]]},"DOI":"10.3816\/ccc.2007.n.032","type":"journal-article","created":{"date-parts":[[2008,9,10]],"date-time":"2008-09-10T21:06:59Z","timestamp":1221080819000},"page":"641-645","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Oxaliplatin and Fixed-Rate Infusional Gemcitabine in the Second-Line Treatment of Patients with Metastatic Colon Cancer: Final Results of a Phase II Trial Prematurely Closed as a Result of Poor Accrual"],"prefix":"10.3816","volume":"6","author":[{"given":"Gilberto","family":"Lopes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose","family":"Quesada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugene","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aurea","family":"Flores","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Afonso","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caio Max","family":"Rocha-Lima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2002","series-title":"Eloxatin\u2122 (oxaliplatin for injection) Prescribing Information [package insert]","key":"10.3816\/CCC.2007.n.032_bib1"},{"key":"10.3816\/CCC.2007.n.032_bib2","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1200\/JCO.2004.05.113","article-title":"FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study","volume":"22","author":"Tournigand","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2007.n.032_bib3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s002800050955","article-title":"Supraadditive effect of 2\u2032,2\u2032-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines","volume":"44","author":"Faivre","year":"1999","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.3816\/CCC.2007.n.032_bib4","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/0006-2952(94)90554-1","article-title":"Schedule dependence of sensitivity to 2\u2032,2\u2032-difluorodeoxycytidine (gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours","volume":"48","author":"Ruiz van Haperen","year":"1994","journal-title":"Biochem Pharmacol"},{"key":"10.3816\/CCC.2007.n.032_bib5","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s002800050492","article-title":"Antitumor activity of prolonged as compared with bolus administration of 2\u2032,2\u2032-difluorodeoxycytidine in vivo against murine colon tumors","volume":"38","author":"Veerman","year":"1996","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.3816\/CCC.2007.n.032_bib6","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1200\/JCO.2005.06.023","article-title":"Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial","volume":"23","author":"Louvet","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2007.n.032_bib7","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/sj.bjc.6602667","article-title":"Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-smallcell lung cancer","volume":"93","author":"Capuzzo","year":"2005","journal-title":"Br J Cancer"},{"key":"10.3816\/CCC.2007.n.032_bib8","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.3816\/CCC.2007.n.032_bib10","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1634\/theoncologist.9-1-8","article-title":"FDA drug approval summaries: oxaliplatin","volume":"9","author":"Ibrahim","year":"2004","journal-title":"Oncologist"},{"key":"10.3816\/CCC.2007.n.032_bib11","doi-asserted-by":"crossref","first-page":"4553","DOI":"10.1200\/JCO.2005.17.749","article-title":"Systemic therapy for metastatic colorectal cancer: current options, current evidence","volume":"23","author":"Kelly","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2007.n.032_bib12","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1200\/JCO.2003.11.126","article-title":"Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial","volume":"21","author":"Rothenberg","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2007.n.032_bib13","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1038\/sj.bjc.6601783","article-title":"A novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal carcinoma","volume":"90","author":"Correale","year":"2004","journal-title":"Br J Cancer"},{"key":"10.3816\/CCC.2007.n.032_bib14","unstructured":"Chang A, Hsin KW, Lim R, et al. Phase II trial of 5-fluorouracil\/ leucovorin\/gemcitabine\/cisplatin as second-line treatment in patients with metastatic or recurrent colorectal carcinoma: a Cancer Therapeutics Research Group study. Clin Colorectal Cancer. In press."},{"key":"10.3816\/CCC.2007.n.032_bib15","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1159\/000092956","article-title":"Multicenter phase II study of gemcitabine and oxaliplatin (GEMOX) as second-line chemotherapy in colorectal cancer patients pretreated with 5-fluorouracil plus irinotecan","volume":"70","author":"Ziras","year":"2006","journal-title":"Oncology"},{"issue":"16 suppl","key":"10.3816\/CCC.2007.n.032_bib16","first-page":"288s","article-title":"Cetuximab with oxaliplatin and capecitabine (CAPOX) in patients with metastatic colorectal cancer (mCRC) refractory to standard chemotherapy","volume":"23","author":"Grothe","year":"2005","journal-title":"J Clin Oncol"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002811703048?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002811703048?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:59:35Z","timestamp":1761519575000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1533002811703048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2007,9]]}},"alternative-id":["S1533002811703048"],"URL":"https:\/\/doi.org\/10.3816\/ccc.2007.n.032","relation":{},"ISSN":["1533-0028"],"issn-type":[{"type":"print","value":"1533-0028"}],"subject":[],"published":{"date-parts":[[2007,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oxaliplatin and Fixed-Rate Infusional Gemcitabine in the Second-Line Treatment of Patients with Metastatic Colon Cancer: Final Results of a Phase II Trial Prematurely Closed as a Result of Poor Accrual","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CCC.2007.n.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}